Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
Is Now a Good Time to Invest In Psychedelics Stocks?
08:36am, Tuesday, 27'th Sep 2022
It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.
Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant
02:37pm, Friday, 09'th Sep 2022 The Motley Fool
They haven't experienced any setbacks, but their shares are still down.
Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant
10:37am, Friday, 09'th Sep 2022
They haven't experienced any setbacks, but their shares are still down.
Teilnahme von atai Life Sciences an Investorenveranstaltungen im September
08:05pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
NEW YORK und BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen für den klinischen Bereich, das sich der Aufgabe ver
atai Life Sciences to Participate in September Investor Events
10:30pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental he
2 Top Trends to Invest $2,000 in Ahead of the Crowd
02:45pm, Monday, 05'th Sep 2022 The Motley Fool
These two trends on the frontier of medicine could present lucrative opportunities for investment.
2 Top Trends to Invest $2,000 in Ahead of the Crowd
10:45am, Monday, 05'th Sep 2022
These two trends on the frontier of medicine could present lucrative opportunities for investment.
7 Psychedelics Stocks to Buy for a Big Drug Boom
03:02pm, Tuesday, 30'th Aug 2022
Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts a
atai Life Sciences legt Finanzergebnisse für das zweite Quartal 2022 und Unternehmens-Update vor
08:09pm, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
- Zusätzliche Laufzeit von voraussichtlich einem Jahr bis 2025 durch Sicherung einer nicht verwässernden Kreditfazilität von Hercules, verbunden mit der Durchführung von Kostenoptimierungen durch
atai Life Sciences sichert sich Laufzeitkreditfazilität in Höhe von bis zu 175 Millionen US-Dollar von Hercules Capital
01:00pm, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
- Eine nicht verwässernde Finanzierungsfazilität plus 312 Mio. US-Dollar an vorhandenen Barmitteln zum 30. Juni 2022 verschafft atai Zugang zu bis zu 487 Mio. US-Dollar, um die Entwicklung von Ther
Atai Life Sciences N.V.'s (ATAI) CEO Florian Brand on Q2 2022 Results - Earnings Call Transcript
01:20pm, Monday, 15'th Aug 2022
Atai Life Sciences N.V. (NASDAQ:ATAI ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financia
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
11:35am, Monday, 15'th Aug 2022 GlobeNewswire Inc.
- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
10:55am, Monday, 15'th Aug 2022 GlobeNewswire Inc.
- Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
10:59am, Monday, 01'st Aug 2022 GlobeNewswire Inc.
NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental hea
atai Life Sciences legt Finanzergebnisse für das zweite Quartal 2022 und Unternehmens-Update vor
10:59am, Monday, 01'st Aug 2022 GlobeNewswire Inc.
NEW YORK (USA) und BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) („atai“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das anstrebt, die Behandl
